Clinical Trial Update: Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of trastuzumab with etoposide in HER-2 positive metastatic breast cancer was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Her-2 Positive Breast Cancer

Drugs mentioned

• Etoposide (Etoposide)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Medstar Health Research Institute | Conditions: HER-2 Positive Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-05-19